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AbsTrACT
Introduction Matching treatment to specific patients 
is too often a matter of trial and error, while treatment 
efficacy should be optimised by limiting risks and costs 
and by incorporating patients’ preferences. Factors 
influencing an individual’s drug response in major 
depressive disorder may include a number of clinical 
variables (such as previous treatments, severity of illness, 
concomitant anxiety etc) as well demographics (for 
instance, age, weight, social support and family history). 
Our project, funded by the National Institute of Health 
Research, is aimed at developing and subsequently 
testing a precision medicine approach to the 
pharmacological treatment of major depressive disorder 
in adults, which can be used in everyday clinical settings.
Methods and analysis We will jointly synthesise data 
from patients with major depressive disorder, obtained 
from diverse datasets, including randomised trials as well 
as observational, real-world studies. We will summarise 
the highest quality and most up-to-date scientific 
evidence about comparative effectiveness and tolerability 
(adverse effects) of antidepressants for major depressive 
disorder, develop and externally validate prediction 
models to produce stratified treatment recommendations. 
Results from this analysis will subsequently inform a 
web-based platform and build a decision support tool 
combining the stratified recommendations with clinicians 
and patients’ preferences, to adapt the tool, increase 
its’ reliability and tailor treatment indications to the 
individual-patient level. We will then test whether use 
of the tool relative to treatment as usual in real-world 
clinical settings leads to enhanced treatment adherence 
and response, is acceptable to clinicians and patients, 
and is economically viable in the UK National Health 
Service.
Discussion This is a clinically oriented study, 
coordinated by an international team of experts, with 
important implications for patients treated in real-
world setting. This project will form a test-case that, 
if effective, will be extended to non-pharmacological 
treatments (either face-to-face or internet-delivered), 
to other populations and disorders in psychiatry (for 
instance, children and adolescents, or schizophrenia and 
treatment-resistant depression) and to other fields of 
medicine.
InTroDuCTIon
Mental disorders are a major cause of the global 
health burden, accounting for 23% of years lived 
with disability.1 With 350 million people affected 
in the world, depressive disorder is considered to 
be the second leading cause of the global health 
burden.2 The burden for major depressive disorders 
is largely due to significant deficits in treatment 
provision.3 There are a number of pharmacological 
and non-pharmacological efficacious interventions 
available for major depressive disorder and the key 
challenge is how best to implement these treatments 
in clinical practice.4 About 80% of people identified 
as suffering from depressive disorder in primary 
care in the UK receive an antidepressant prescrip-
tion in the first year of diagnosis.5 However, the 
majority of prescriptions are for less than 30 days,5 
while an adequate trial of antidepressants is gener-
ally recommended to be 6–8 weeks before changing 
or stopping the medication. Too short a duration 
of treatment both limits the therapeutic effect6 and 
increases the risk of withdrawal symptoms because 
antidepressants should be tapered off over a period 
of 4 weeks or more.
While a number of factors contribute to subop-
timal treatment durations, two of the most promi-
nent ones are the initial side effects of the medication 
and their perceived marginal efficacy. These factors 
are exacerbated by our current inability to predict 
which drug(s) will cause side effects in which 
patients, and which drug(s) will work most effec-
tively for which patients. Better means of tailoring 
treatment to individuals are urgently needed. This 
has been recognised by important institutions (for 
instance, the National Institute for Health and Care 
Excellence in the UK or the Royal Australian and 
New Zealand College of Psychiatrists in Australia), 
although there are no reliable ways of doing so, to 
the best of our knowledge.7 Over the last few years, 
however, there has been a substantial accumulation 
of clinical trial data as well as long-term outcomes 
from ‘real-world’ datasets. The wealth of this avail-
able data, together with the development of new 
methods in evidence synthesis, has created major 
opportunities to improve patient outcomes by 
using existing therapies more efficiently, in a more 
targeted manner.8 Recent models have been able 
to predict the probability of response for a specific 
subgroup of patients with depressive disorder or 
estimate the chances that an individual will have 
a particular side effect.9 By identifying and then 
matching individual antidepressants to individual 
patients, clinicians can more precisely customise 
treatment to patients’ needs and thus improve their 
outcome.10
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Figure 1 Overview of the project to develop and validate the 
personalise antidepressant treatment for unipolar depression combining 
individual choices, risks and big data treatment algorithm. Evidence 
from individual patient data from antidepressant trials in major 
depressive disorder, in combination with real-word (observational) data 
and patient and clinician preferences (phase I), will be used to develop 
a web-based personalised treatment algorithm (phase II). The web-
based algorithm will be tested in a multicentre, pragmatic, randomised 
controlled trial comparing the treatment algorithm with usual care 
(Phase 3).
Despite recent progress in this field,11 psychiatry continues 
to lag behind other specialties like cardiology, oncology, immu-
nology and neurology. Currently, no validated system of tailoring 
treatment choices is available. Indeed, matching treatment to 
specific patients is too often a matter of trial and error, while 
treatment efficacy should be optimised by limiting risks and 
costs and by incorporating patients’ preferences.10 A joint anal-
ysis of individual participant data obtained from multiple clinical 
trials as well as real-world studies, has the potential to provide 
‘personalised’ estimates of comparative effectiveness, but also to 
provide ‘individualised’ predictions regarding the probability of 
response to treatment and of experiencing side effects.4 Factors 
influencing an individual’s drug response in depressive disorder 
may include a number of clinical variables (such as number and 
types of previous treatments, severity of illness, concomitant 
anxiety etc) as well demographics (for instance, age, weight, 
social support and family history).4
However, the wealth and variety of all possible such factors 
create its own challenges and new approaches are needed. These 
approaches should12:
 ► Be based on robust evidence.
 ► Be acceptable to patients and clinicians.
 ► Guide treatment personalisation, incorporating patients’ 
views and preferences and clinical judgement.13
 ► Support probabilistic decision-making.14
Our project, funded by the National Institute of Health 
Research, is aimed at developing and subsequently testing a 
precision medicine approach to the pharmacological treatment 
of major depressive disorder, which can be used in everyday 
clinical settings. To this aim, we will jointly synthesise data 
from patients with depressive disorder, obtained from diverse 
datasets, including both randomised trials as well as obser-
vational, real-world studies. Results from this analysis will 
subsequently inform a web-based platform, which will allow 
shared decision-making at the individual-patient level during 
the routine consultation between clinicians and patients (see 
figure 1).
MeThoDs AnD AnAlysIs
This project is called ‘personalise antidepressant treatment for 
unipolar depression combining individual choices, risks and big 
data’ (PETRUSHKA) and its overarching objectives are to:
1. Summarise the highest quality and most up-to-date scientif-
ic evidence about comparative effectiveness and tolerability 
(adverse effects) of antidepressants for major depressive dis-
orders in adults, develop and externally validate prediction 
models to produce stratified treatment recommendations.15
2. Build a decision support tool combining the stratified rec-
ommendations with clinicians and patients’ preferences, to 
adapt the tool, increase its reliability and tailor treatment in-
dications to the individual-patient level.
3. Test whether use of the tool relative to treatment as usual in 
real-world clinical settings leads to enhanced treatment ad-
herence and response, is acceptable to clinicians and patients, 
and is economically viable.
To achieve these objectives, the project is structured in three 
phases: (1) development and validation of the models that 
predict clinical outcomes for patient subgroups and different 
treatments, (2) building a treatment algorithm, (3) designing and 
conducting a pragmatic randomised trial to evaluate the useful-
ness of the algorithm. Patients and clinicians will be involved 
throughout the project to understand preferences and values in 
relation to clinical outcomes; and acceptability of and trust in 
the decision support tool.
 Phase I: development of prediction models, using randomised 
and real-world evidence
When several treatment options are available, standard 
meta-analyses provide only partial information on relative treat-
ment effects because they can only compare two treatments at 
a time.16 This fragmented approach does not support optimal 
clinical decision making17 and the need for a robust method 
to summarise evidence across several interventions has been 
increasingly recognised.18 Network meta-analysis (NMA) has 
been developed to allow the estimation of the relative effect 
of many treatments one against the other and produce ranked 
treatment options.19
In this project, we will use aggregate and individual-patient 
data (IPD) from multiple sources, combining methods from IPD 
network meta-regression and prognostic modelling.20 Our aim 
will be to predict the effects (in terms of efficacy, acceptability 
and tolerability) of different antidepressants given information 
on patient-level characteristics. Our models will incorporate a 
range of possible prognostic factors and effect modifiers. We will 
use information on both demographic (ie, gender, age, ethnicity, 
marital status, childhood trauma) as well as clinical characteris-
tics (ie, family history, previous episodes, past treatments, age 
at onset, duration of index episode, severity, treatment dose, 
concomitant medication, comorbidity).21 We will explore a range 
of alternative modelling approaches, incorporating evidence 
from both randomised and observational evidence, utilising and 
further extending recently proposed methods.22 In addition, we 
will explore advanced machine learning techniques for prog-
nostic modelling, such as artificial neural networks and support 
vector machines.23 We will finally choose the best performing 
models for each outcome using extensive cross-validation.
The randomised studies selected for the IPD analysis will 
follow the same selection criteria as our previously published 
NMA based on aggregate data.24 The review protocol with all 
the methodological details has already been published.25 We are 
aware that not all of the studies selected for inclusion will have 
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data available at the individual patient level; however, we will 
systematically request access by contacting study authors and/
or sponsors and by submitting applications via online platforms. 
To complement the randomised data and to also collect infor-
mation about long-term outcomes (especially adverse events), 
we will use large observational datasets. Real-world routinely 
collected data may be more representative of the patient popula-
tion seen in everyday clinical practice. These data will contribute 
by providing relevant information on the natural course of 
the condition and the prevalence of various important patient 
characteristics. We aim to use data from both primary care 
(QResearch - https://www. qresearch. org/), as well secondary 
care (UK Clinical Record Interactive Search).26
After model development, in order to externally validate all 
of our models we will use a part of the observational data as 
‘ground truth’ test data (‘held-out data’). We will select a specific 
subgroup of the data, for example, data collected in a specific 
geographic location and use this approach to test our models, 
that is, to assess their predictive performance in real-world 
settings. Overall, our approach aims to harness the strengths of 
both randomised and observational data.
 Phase 2: development of the treatment algorithm
We will then develop a clinical support system (treatment algo-
rithm), to guide clinicians, patients and carers in the shared 
process of decision-making in routine care. Treatment algo-
rithms have contributed to advances in many fields of medi-
cine and psychiatry,27 and computerised decision systems have 
been developed to provide ongoing assistance to clinicians.28 
However, existing algorithms in psychiatry lack the ability to 
apply the best knowledge directly to the individual patient and 
selectively provide information relevant to the characteristics 
and circumstances of that patient in their specific situation.
We will develop a web-based algorithm that will:
 ► Utilise the predictions from the predictive models developed 
in phase I.
 ► Incorporate preferences and values of clinicians and patients 
to identify the desired clinical outcome,29 30 considering 
both efficacy and adverse events (for instance, some patients 
may want to avoid sedation while others tremor or sexual 
dysfunction).
 ► Generate the corresponding ranking list of personalised 
treatment recommendations that will inform the clinical 
discussion between clinicians and patients, and the final 
treatment decision.
The algorithm will be implemented in the form of a web appli-
cation, accessible from any computer or tablet. The input of the 
algorithm will be a patient’s individual characteristics and pref-
erences. The output will be the models’ estimates regarding the 
expected outcomes under each treatment, and a proposed treat-
ment ranking according to the patients’ preferences.
During the development of the algorithm, we will organise 
a series of focus groups with patients, carers and clinicians to 
gather feedback about the layout of the decision tool, its clinical 
value, practical utility, and ways to improve it.
Phase 3: randomised trial
We will conduct a two-arm, multicentre, open-label, randomised 
controlled trial comparing the treatment algorithm with care as 
usual. The primary objective of the trial is to determine whether 
using the treatment algorithm to identify a ‘personalised’ anti-
depressant results in an increased proportion of patients who 
keep taking the allocated treatment at 8 weeks, in comparison to 
care as usual. The secondary objectives are to: (1) assess whether 
using the treatment algorithm results in greater reduction of 
depressive symptoms and better adherence to treatment in the 
long-term; (2) determine the impact on societal costs and cost-ef-
fectiveness/cost-utility of the treatment algorithm; (3) explore 
how the treatment algorithm is used by various stakeholders 
(patients, carers, clinicians), what they think about it and the 
impact this has on care and care processes, in order to refine its 
future implementation in the UK and across different countries.
The treatment algorithm described in phase II will be the 
intervention, and the control condition will be treatment as 
usual (ie, clinician prescribing antidepressants without the use of 
the algorithm). In terms of the study population, we will include 
males or females, aged 18 years old or above, with a diagnosis 
of a major depressive episode (either first episode or recur-
rent) according to standardised criteria and requiring treatment 
with antidepressant as monotherapy, who are able to provide 
informed consent. Patients with treatment resistant depression, 
bipolar disorder, psychosis, substance abuse or current suicidal 
ideation and those requiring urgent mental healthcare or admis-
sion will be excluded.
Participants will be recruited from clinical services (general 
practitioner surgeries or outpatient clinics) in centres across the 
UK. Patients with major depressive disorder will be considered 
for the study if the clinician decides to prescribe an antidepres-
sant to treat the depressive disorder. Participants will be provided 
with a brief explanation of the study and a baseline visit will be 
scheduled. The majority of the recruitment is expected to be in 
primary care as this is where patients with depressive disorder 
are seen most often; however, patients from secondary care will 
also be included in order to increase the generalisability of the 
findings from this trial.
The primary outcome will be acceptability of antidepressant 
treatment, measured as the number of participants stopping 
treatment (or changing medication) by week 8 (all-cause discon-
tinuation). This measure integrates patients’ and clinicians’ 
judgments of efficacy and tolerability into a global measure of 
effectiveness.24
Secondary outcomes will focus on both short-term and long-
term outcomes, including self-rated change in depressive symp-
toms measured via remote monitoring, observer-rated change 
in depressive symptoms, discontinuation due to adverse events 
only, tolerability of antidepressants and structured question-
naires to measure direct and indirect costs throughout the study. 
To evaluate the algorithm, follow-up interviews with a subgroup 
of patients and clinicians will also be performed.
Based on available data,24 an absolute difference of 10% in 
all-cause dropout (primary outcome) is considered clinically 
relevant at 8 weeks. For a rate of 25% in the control group, 
compared with 15% in the experimental arm, the trial will 
have 80% power with 248 patients in each arm (alpha 0.05), 
assuming that 5% of participants will be lost to follow-up. Anal-
yses will be conducted using Mixed Models Repeated Measures 
for missing data. Mixed effects logistic model will be used to 
explore treatment effects on dichotomous outcomes. For contin-
uous outcomes, mixed effects linear model will be used to esti-
mate treatment effects with a baseline severity included as a 
covariate.
The Oxfordshire NHS Research Ethics Committee will review 
the trial protocol. Before the screening visit, participants will 
receive an information sheet with all information about the 
study and will provide informed consent. The Trial Management 
Group and the Trial Steering Committee will independently 
monitor the conduct of the trial.
Bern. Protected by copyright.
 o
n
 O
ctober 28, 2019 at Universitaetsbibliothek
http://ebm
h.bmj.com/
Evid Based M
ental Health: first published as 10.1136/ebm
ental-2019-300118 on 23 O
ctober 2019. Downloaded from
 
4 Tomlinson A, et al. Evid Based Ment Health 2019;0:1–5. doi:10.1136/ebmental-2019-300118
Protocol
PATIenT AnD PublIC InvolveMenT AnD PArTICIPATIon
Patients and members of the public will be actively involved 
throughout the research project, as follows:
 ► Project management: management of the research project, 
being part of the steering committee and the advisory group.
 ► Study design: contributing to design and layout of the treat-
ment algorithm, and the trial protocol.
 ► Design of informed consent materials: developing under-
standable consent and information sheets for people taking 
part in the trial.
*Member of the research team:
 ► Participation in carrying out some aspects of the research 
(eg, focus groups).
 ► Participation in interpretation of results of the research.
*Dissemination of findings: (eg, contributing to the writ-
ing-up and presentation of the outcomes from the project) and 
making sure the research is reported is communicated clearly 
and appropriately.
All patient and public involvement and engagement (PPIE) 
activities will be organised in collaboration with the Patients and 
Research Group, a group comprised of patients, carers and public 
members together with staff members from across mental health 
research and care within the NHS in Oxfordshire and Bucking-
hamshire, under the Oxford Health Biomedical Research Centre 
PPIE programme.
DIsCussIon
This is a clinically relevant project, coordinated by an inter-
national team of experts and with important implications for 
patients in the NHS. The main potential barriers to success are 
the access to individual-level data (for the algorithm) and poor 
recruitment (for the trial). Access to pharmaceutical company 
data proved challenging in the previous projects, but recent 
changes in policy have helped.31 Obtaining IPD is challenging, 
but our work in the field and our extensive network of collabo-
rators will materially help.32
Another challenge is that the data from randomised trials will 
be gathered via highly standardised forms, whereas observa-
tional data will be lacking in standardisation. However, some 
critical outcomes like drug discontinuation are the same and 
other measures can be shown to correspond across the apparent 
methodological divide.33 In two recent examples, observational 
data corroborated findings from randomised trials, increasing 
the precision of treatment estimates.22 Observational studies 
complement randomised evidence and address some of its 
limitations, such as short follow-up time, small sample size, 
highly selected study populations and scant information about 
side effects. Truly representative samples are required to identify 
which prognostic factors (analysed with effect modifiers from 
randomised trials) have real-world predictive value. Applying 
the methodology to individual patient data will be the key inno-
vative step within this study.
The pilot trial cannot be run in a blind fashion. The treat-
ment algorithm will generate a list of drugs based on the best 
available data from randomised trials and observational data-
sets, but patients and clinicians will then be able to enter their 
own preferences in the web-based algorithm (for instance, the 
adverse events they want to avoid or the specific antidepressant 
they prefer). The weighting of these preferences will change and 
personalise the final ranking of treatment options. Participants 
will be seen in their usual clinical setting (primary or secondary 
care, respectively), so that the intervention occurs in a real-world 
setting. The advantages of individual randomisation outweigh 
clustering because the algorithm is in essence personal and so the 
solution for one person does not generalise to another individual 
with different characteristics or preferences.
There are two main ethical issues arising from this project: (1) 
confidentiality of data and (2) the use of public data to generate 
intellectual property. To protect patients’ confidentiality, all data 
used in this project will be anonymised or pseudo-anonymised. 
Data from randomised trials and observational data will be 
subject to an agreed and binding confidentiality agreement with 
the study sponsor.
The project will only focus on drug treatment, rather than 
including psychological interventions for two reasons: (1) anti-
depressants are the most commonly used treatment for major 
depressive disorder worldwide and (2) data collected from 
antidepressant trials are similar and reliable enough to allow 
the innovative analyses that are necessary to stratify and rank 
treatments for each individual. However, our study will form 
a test-case. If shown to work adequately, the algorithm can be 
modified and adapted to cover different treatments (ie, psycho-
logical interventions, either face-to-face or internet-deliv-
ered), other populations of patients (for instance, children and 
adolescents) and other psychiatric disorders (ie, schizophrenia 
or bipolar disorder). It can also be used in other non-commu-
nicable diseases, where the relationship between clinicians and 
patients spans over a long period of time and patients’ prefer-
ences are crucial to determine which is the treatment of choice 
and increase adherence to treatment.
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